BEIJING, Sept 2 (Reuters) - China granted emergency use authorisation to Livzon Pharmaceutical Group Inc's COVID-19 vaccine as a booster, the company said on Friday, one of just two new products against the disease the country has cleared in more than a year.
Livzon Pharmaceutical Group was recognized as the National Enterprise Technology Center with High Scores
A Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed and manufactured by Livzon has shown good protective effects against the Omicron variant in a phase III clinical booster trial
Livzon Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) approved by China NMPA.
A potential COVID-19 vaccine developed by a subsidiary of China's Livzon Pharmaceutical Group Inc appeared safe and able to elicit antibodies in healthy adults in a mid-stage clinical trial, Chinese researchers said.
BEIJING (Reuters) - China’s medical products regulator has approved clinical trials for a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc, the Chinese company said late on Tuesday.
Livzon participated in the 39th Annual JP Morgan Medical Health Conference
LTS Lohmann Therapie-Systeme AG (“LTS”), a world class pharmaceutical technology company headquartered in Andernach, Germany, and Livzon Pharmaceutical Group Inc. (000513.SZ,1513.HK) (“Livzon”), a leading PRC pharmaceutical company, announced today that the companies have entered into an exclusive license and collaboration agreement (the “Agreement”). LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).
Livzon Won the 19th China Patent Award of Excellence